Johnson & Johnson Vision announced March 12 that it had gained US FDA approval for the Tecnis PureSee, an extended depth of focus (EDOF) intraocular lens (IOL) for use in cataract surgery.

The Jacksonville, Florida, company said the lens would be available for US patients later in 2026.

The PureSee is a purely refractive EDOF IOL that is designed to deliver uninterrupted, high-quality vision from distance through intermediate with functional near vision, while maintaining contrast sensitivity and low-light performance. The lens was first approved in Europe in 2024 and is also approved in Canada, Japan, and Latin American markets.

J&J Vision said the PureSee is the only FDA‑approved EDOF IOL with no warning in its labeling on loss of contrast sensitivity, delivering low-light performance comparable to an aspheric monofocal IOL.

The company said that 97 percent of patients reported no very bothersome visual disturbances and would recommend the lens to friends or family.

Erin Powers, president, North America, Johnson & Johnson Surgical Vision, told Healio: “Surgeons are increasingly looking for presbyopia‑correcting options that balance range of vision with visual quality, and Tecnis PureSee IOL was designed with that balance in mind.”

Other lenses in the Tecnis line include the Odyssey trifocal and the Eyhance, a monofocal-plus lens designed to slightly extend depth of focus.

More News

Want to Read Locked Articles?

Already Have an Account?

Register A Corporate Account

Topics of Interest

Products of Interest